Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease
- Atrogi’s breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic disease
- First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential in obesity, diabetes, and age-related muscle loss
- ATR-258 is set to enter Phase 2 trials to confirm its ability to deliver exercise-like benefits, including fat loss, improved muscle strength, and better metabolic control, alone or in combination with GLP-1 therapies
Stockholm, Sweden, June 23, 2025 – Atrogi AB, a clinical-stage biotechnology company pioneering muscle-targeted therapies, today announces the publication of a landmark study in the prestigious scientific journal Cell, titled “GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.” This paper highlights Atrogi’s first-in-class oral β2-adrenergic receptor agonist, ATR-258, which precisely activates skeletal muscle metabolism through novel GRK2-biased signaling. This transformative approach enhances glucose uptake and improves body composition by reducing fat and preserving lean muscle without the cardiovascular risks typically associated with β2-agonists.
